Physician profile
Alitza Ford
NPI 1356346886
$6,667.02
in general payments reported to CMS, 2019-2025
32 companies · $567 in 2025
The $567 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,345 · 2022: $1,503 · 2023: $1,782 · 2024: $1,470 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,819.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,362.59 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $792.64 | 2021-2025 | Trulance, Xifaxan |
| Redhill Biopharma INC. | $740.94 | 2021-2025 | Talicia, Movantik, Aemcolo |
| Janssen Biotech, INC. | $565.96 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $381.93 | 2021-2025 | Gattex, Entyvio, Eohilia |
| Intercept Pharmaceuticals, INC. | $257.26 | 2021-2024 | |
| Pfizer INC. | $254.18 | 2021-2025 | |
| Celgene Corporation | $251.17 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $233.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $231.74 | 2023-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $230.39 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $182.99 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $133.34 | 2021-2022 | |
| Evoke Pharma, INC. | $132.72 | 2021-2023 | Gimoti |
| Ardelyx, INC. | $120.63 | 2024-2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $102.03 | 2024 | Iqirvo, Bylvay |
| Qol Medical, LLC | $78.77 | 2022-2025 | Sucraid |
| Genzyme Corporation | $76.38 | 2022-2023 | |
| Daiichi Sankyo INC. | $74.88 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $57.63 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $53.34 | 2024-2025 | Vowst |
| Myriad Women'S Health, INC. | $51.04 | 2023 | Myrisk |
| Celltrion USA INC. | $48.03 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $47.43 | 2021-2025 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $38.00 | 2022 | |
| Fresenius Kabi USA, LLC | $37.89 | 2023-2024 | Idacio |
| Ethicon US, LLC | $28.49 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $25.46 | 2025 | Givlaari |
| Ironwood Pharmaceuticals, INC | $24.27 | 2023 | Linzess |
| Gilead Sciences, INC. | $22.90 | 2024 | |
| Echosens North America, INC. | $17.20 | 2022 | |
| Alexion Pharmaceuticals, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alitza Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.